Who do we help?

Our group of prognostic and predictive blood biomarkers – GlyHealth,  reliably measure and track chronic inflammation processes in the body. Unlike current inflammation markers, this is done without interference from acute inflammation and can give early warning signs even at very early subclinical stages of inflammatory diseases. Blood tests based on these biomarkers can also be used to track fitness of immune system and effectiveness of anti-inflammatory intervention

Individuals

Individuals who are either patients with IDs or those not formally diagnosed with an ID but at high risk of developing one or more IDs in the near future.

BIOPHARMA, GLYCOANALYSIS, IBD, CLINICAL TRIALS PRECISION MEDICINE

Clinicians

Clinicians and other health care practitioners responsible for the care of patients either with or at risk of developing IDs.

Biopharma

Biopharma companies developing anti-inflammatory therapeutics.

How do we help?